ArticleThoracic cancer2026
Tumor Necrosis on Routine Pretreatment CT as a Potential Prognostic Marker in Advanced NSCLC Treated With Immune Checkpoint Inhibitor Monotherapy: A Two-Center Retrospective Study.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of CT-detected tumor necrosis in advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor (ICI) monotherapy remains unclear. This two-center retrospective study investigated whether tumor necrosis on pretreatment CT independently predicts overall survival (OS).
methodsA total of 151 advanced NSCLC patients who received ICI monotherapy between March 2016 and August 2021 at two Japanese institutions were retrospectively analyzed. Tumor necrosis was visually assessed and operationally defined as an intratumoral area of low attenuation or cavitary lesion ≥ 5 mm on pretreatment chest CT (contrast-enhanced in 113 patients [75%] and non-contrast in 38 [25%]). Cox regression analyses identified independent prognostic factors for OS, with internal validation using 1000 bootstrap resamples.
resultsAmong 151 patients (mean age 69 years; 90% with ECOG PS 0-1), 121 (80%) had CT-detected necrosis. Median OS was significantly shorter in necrosis-positive patients than in necrosis-negative patients (374 vs. 1035 days; log-rank p = 0.02). A multivariate Cox regression analysis identified tumor necrosis as an independent adverse prognostic factor (HR = 1.84, 95% CI = 1.03-3.30; p = 0.04), along with blood-based biomarkers, tumor size, and PD-L1 expression. The detection rate of necrosis differed between CT modalities (contrast-enhanced 84% vs. non-contrast 68%, p = 0.04).
conclusionThis exploratory two-center retrospective study indicates the potential of CT-detected tumor necrosis as a readily accessible prognostic marker in ICI-treated NSCLC. However, the results obtained require validation in larger, prospective, multicenter studies with standardized CT imaging protocols before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.